Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

被引：0
|
作者：
Rami S. Komrokji
Avani M. Singh
Najla Al Ali
Onyee Chan
Eric Padron
Kendra Sweet
Andrew Kuykendall
Jeffrey E. Lancet
David A. Sallman
机构：
[1] H. Lee Moffitt Cancer Center & Research Institute,Department of Malignant Hematology
[2] University of South Florida & Moffitt Cancer Center,Department of Hematology/Oncology
来源：
Blood Cancer Journal | / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
    Komrokji, Rami S.
    Singh, Avani M.
    Al Ali, Najla
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew
    Lancet, Jeffrey E.
    Sallman, David A.
    BLOOD CANCER JOURNAL, 2022, 12 (11)
  • [2] Assessing the Role of Venetoclax in Combination with Hypomethylating Agents in Higher Risk Myelodysplastic Syndromes
    Komrokji, Rami S.
    Al Ali, Najla
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew T.
    Lancet, Jeffrey E.
    Sallman, David A.
    BLOOD, 2021, 138
  • [3] Venetoclax Combination with Hypomethylating Agents for Treatment of Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Nelson, Rebecca
    Talati, Chetasi
    Kuykendall, Andrew
    Sweet, Kendra
    Padron, Eric
    Lancet, Jeffrey
    List, Alan
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S339 - S340
  • [4] Survival Advantage with Hypomethylating Agents In Patients with Higher Risk Myelodysplastic Syndrome
    Park, Young-Hoon
    Lee, Je-Hwan
    Lee, Kyoo Hyung
    Lee, Jung-Hee
    Kim, Dae-Young
    Kim, Sung-Doo
    Lim, Sung-Nam
    Choi, Yunsuk
    Seol, Mice
    Lee, Young-Shin
    Kang, Young-A
    Jeon, Mijin
    BLOOD, 2010, 116 (21) : 775 - 775
  • [5] No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
    Sohn, Sang Kyun
    Moon, Joon Ho
    Lee, In Hee
    Ahn, Jae Sook
    Kim, Hyeoung Joon
    Chung, Joo Seop
    Shin, Ho Jin
    Park, Sung Woo
    Lee, Won Sik
    Lee, Sang Min
    Kim, Hawk
    Lee, Ho Sup
    Kim, Yang Soo
    Cho, Yoon Young
    Bae, Sung Hwa
    Lee, Ji Hyun
    Kim, Sung Hyun
    Song, Ik Chan
    Kwon, Ji Hyun
    Lee, Yoo Tin
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2018, 33 (06): : 1194 - 1202
  • [6] Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
    Bazinet, Alexandre
    Desikan, Sai Prasad
    Li, Ziyi
    Rodriguez-Sevilla, Juan Jose
    Venugopal, Sangeetha
    Urrutia, Samuel
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Chien, Kelly S.
    Hammond, Danielle
    Kanagal-Shamanna, Rashmi
    Ganan-Gomez, Irene
    Kadia, Tapan M.
    Borthakur, Gautam
    Dinardo, Courtney D.
    Daver, Naval G.
    Jabbour, Elias J.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1319 - 1326
  • [7] Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents
    Sekeres, Mikkael A.
    LEUKEMIA & LYMPHOMA, 2015, 56 (12) : 3267 - 3269
  • [8] Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents
    Itzykson, Raphael
    Fenaux, Pierre
    LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 760 - 762
  • [9] Updated Efficacy of Eltanexor Monotherapy in Patients with Higher Risk Hypomethylating Myelodysplastic Syndrome Primary Refractory to Hypomethylating Agents
    Lee, Sangmin
    Mohan, Sanjay R.
    Knupp, Jessica
    Chamoun, Kamal
    Karasik, Igor
    Bai, Vicky Xiang
    Ingalls, Kimberly
    FanYang
    Shah, Jatin J.
    Kauffman, Michael G.
    Shacham, Sharon
    Bhatnaga, Bhavana
    BLOOD, 2021, 138 : 3676 - +
  • [10] Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
    Xiao, Yunshuo
    Yang, Kun
    Huang, Qiuying
    Wei, Changqing
    Wei, Manlv
    Geng, Zhili
    Wu, Hui
    Zhou, Tianhong
    Yin, Xialoin
    Zhou, Yali
    FRONTIERS IN ONCOLOGY, 2024, 14
12345